Opyl is an innovative Australian digital health company that harnesses artificial intelligence to enhance clinical trial design and predict outcomes. Aimed at empowering clinical researchers, biopharmaceutical firms, and medical investors, the platform offers a robust tool known as TrialKey, which utilizes AI and GPT-4 to analyze extensive data from historical clinical trials. This pioneering approach achieves a remarkable accuracy rate of over 90% in predicting trial success while also providing insights and recommendations to overcome trial challenges, ultimately accelerating medical research efforts.
• ai-powered clinical trial prediction
• clinical trial design optimization
• high accuracy rate of +90%
• utilizes real-world trial data
• tailored insights and recommendations
Average Rating: 0.0
5 Stars:
0 Ratings
4 Stars:
0 Ratings
3 Stars:
0 Ratings
2 Stars:
0 Ratings
1 Star:
0 Ratings
No ratings available.
Patient centric platform for clinical trials enhancing patient engagement and compliance through AI.
View DetailsAI-driven platform for simulating clinical trials and generating synthetic evidence.
View DetailsAI-powered platform creating digital twins for optimizing clinical trials.
View DetailsA federated AI framework that integrates decentralized data sources for AI development.
View Details